Neuromodulation : journal of the International Neuromodulation Society
-
1) To characterize patterns of globus pallidus interna neural synchrony in patients with secondary dystonia; 2) to determine whether neural hypersynchrony in the globus pallidus externa (GPe) and interna (GPi) is attenuated during high frequency deep brain stimulation (HF DBS) in a patient with DYT3+ dystonia and in a patient with secondary dystonia due to childhood encephalitis. ⋯ These results suggest that beta hypersynchrony, demonstrated now in both primary and secondary dystonia, may play a pathophysiological role in pathological hyperkinesis. Further investigation is needed in a larger cohort of well-characterized primary and secondary dystonia patients.
-
We demonstrate that confocal Raman mapping spectroscopy provides rapid, detailed, and accurate neurotransmitter analysis, enabling millisecond time resolution monitoring of biochemical dynamics. As a prototypical demonstration of the power of the method, we present real-time in vitro serotonin, adenosine, and dopamine detection, and dopamine diffusion in an inhomogeneous organic gel, which was used as a substitute for neurologic tissue. ⋯ Accurate nondestructive characterization for real-time detection of neurotransmitters in inhomogeneous environments without the requirement of sample labeling is a key issue in neuroscience. Our work demonstrates the capabilities of Raman spectroscopy in biological applications, possibly providing a new tool for elucidating the mechanism and kinetics of deep brain stimulation.
-
To investigate in people with spastic paraparesis (SP): 1) the factors contributing to foot drop and reduced toe clearance while walking; 2) short-term effects of bilateral functional electrical stimulation (FES) of the common peroneal nerve. ⋯ There are multiple causes of tripping in people with SP; FES reduces foot drop and improves walking speed.
-
To quantify the overall and disaggregated societal costs of intrathecal drug delivery systems (IDDSs) in the treatment of pain and spasticity in the United States. ⋯ The societal costs for IDDS patients are high and extremely variable. A relatively small number of patients made an extreme number of medical encounters and represent a heavy societal cost burden. In order to reduce the growing societal cost of chronic pain and spasticity treatment, measures should be taken to reduce the resource utilization and costs of the most challenging patients.